Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery

European Journal of Clinical Pharmacology

Volumn 52, Issue 1, 1997, Pages 31-35

  Russmann, S ^a   Gohlke Barwolf C ^a   Jahnchen E ^a   Trenk, D ^a   Roskamm, H ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

age dependence; anticoagulant drugs; individual metabolism sensitivity; phenprocoumon; postoperative dosage requirement; thromboembolism prophylaxis

Indexed keywords

PHENPROCOUMON;

ADULT; AGE; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FEMALE; HEART VALVE REPLACEMENT; HEART VALVE SURGERY; HUMAN; MALE; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; PHENPROCOUMON;

EID: 0030889440     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050245     Document Type: Article

References (24)

1. Toohey M (1953) Clinical trial of phenylindanedione as an anticoagulant. Br Med J 1: 650-652
2. Husted S, Andreasen F (1977) The influence of age on the response to anticoagulants. Br J clin Pharmac 4: 559-565
3. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH (1977) Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 4: 315-320
4. Gurwitz JH, Avron J, Ross-Degnan D, Choodnovskiy I, Ansell J (1992) Ageing and the anticoagulant response to warfarin therapy. Ann Intern Med 116: 901-904
5. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F (1995) The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 40: 203-207
6. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124: 970-978
7. Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87: 144-152
8. Petitti DB, Strom BL, Melmon KL (1989) Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 42: 759-764
9. 1-epoxide cycle in rats. J Pharm Pharmacol 32: 828-832
10. Willingham AK, Matschiner JT (1974) Changes in phylloquinone epoxide activity related to prothrombin synthesis and microsomal clotting activity in the rat. Biochem J 140: 435-441
11. O'Malley K, Stevenson KH, Ward CA, Wood AJJ, Crooks J (1977) Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmac 4: 309-314
12. Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH (1985) Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 13: 213-227
13. Schmucker DL (1985) Ageing and drug disposition: An update. Pharmacol Rev 37: 133-148
14. Durnas CH, Loi Cho-Ming, Cusack BJ (1990) Hepatic drug metabolism and aging. Clin Pharmacokinet 19: 359-389
15. Trenk D, Althen H, Jähnchen E, Meinertz T, Øie S (1987) Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol 33: 49-54
16. Quick AJ (1938) The nature of bleeding in jaundice. J Am Med Ass 110: 1658-1662
17. Koch-Weser J, Sellers EM (1971) Drug interactions with coumarin anticoagulants. N Engl J Med 285: 487-498
18. Redwood M, Taylor C, Bain BJ, Matthews JH (1991) The association of age with dosage requirement for warfarin. Age Ageing 20: 217-220
19. Toon S, Heimark LD, Trager WF, O. Reilly RO (1985) Metabolic fate of phenprocoumon in humans. J Pharm Sci 74: 1037-1041
20. Gugler R, Dengler HJ (1973) Arzneimittelinteraktionen mit oralen Antikoagulantien vom Cumarintyp. Klin Wochenschr 51: 1081-1090
21. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW (1975) Antipyrine metabolism in man: influence of age. alcohol, caffeine, and smoking. Clin Pharmacol Ther 18: 425-432
22. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M (1994) Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37: 563-569
23. Routledge PA, Chapman PH, Davies DM, Rawlins MD (1979) Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol 8: 243-247
24. Meinertz T, Gilfrich H-J, Groth U, Jonen H-G, Jähnchen E (1977) Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmcol Ther 21: 6: 731-735